HMMR and neoplasm: Notably, induction of one HMMR transgene allele increased the tumor incidence to 72.0% (18/25) and reduced latency to 29.5 weeks (95% CI, 25.6–33.4 weeks); and induction of the two HMMR transgene alleles further increased tumor incidence to 80.0% (20/25) and reduced latency to 25.5 weeks (95% CI, 21.3–29.8 weeks; log-rank p = 0.0038; Fig. 3a).